PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic xp11 translocation renal cancers: Clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity

American Journal of Surgical Pathology

Volumn 39, Issue 9, 2015, Pages 1181-1196

  Rao, Qiu ^a   Shen, Qin ^a   Xia, Qiu Yuan ^a   Wang, Zi Yu ^d   Liu, Biao ^a   Shi, Shan Shan ^a   Shi, Qun Li ^a   Yin, Hong Lin ^a   Wu, Bo ^a   Ye, Sheng Bing ^a   Li, Li ^e   Chen, Jie Yu ^a   Pan, Min Hong ^b   Li, Qing ^c   Li, Rui ^a   Wang, Xuan ^a   Zhang, Ru Song ^a   Yu, Bo ^a   Ma, Heng Hui ^a   Lu, Zhen Feng ^a   Zhou, Xiao Jun ^a   more..

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Nanjing Maternity and Child Health Care Hospital   (China)

^d NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^e ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

FISH; Melanotic Xp11 translocation renal cancer; Molecular genetics; Perivascular epithelioid cell tumor; PSF SFPQ; Rearrangement; TFE3; Translocation

Indexed keywords

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; PTB-ASSOCIATED SPLICING FACTOR; RNA BINDING PROTEIN; TFE3 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; CHEMISTRY; CHILD; CLASSIFICATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; MALE; MELANOMA; MIDDLE AGED; MITOSIS; MOLECULAR DIAGNOSIS; MORTALITY; PATHOLOGY; PERIVASCULAR EPITHELIOID CELL TUMOR; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; X CHROMOSOME;

ADOLESCENT; ADULT; AGED; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CHILD; CHROMOSOMES, HUMAN, X; FEMALE; GENE FUSION; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; MITOSIS; MOLECULAR DIAGNOSTIC TECHNIQUES; PERIVASCULAR EPITHELIOID CELL NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; TIME FACTORS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84942765876     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000502     Document Type: Article

References (61)

1. Argani P. The evolving story of renal translocation carcinomas. Am J Clin Pathol. 2006;126:332-334.
2. Argani P, Aulmann S, Illei PB, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34:1395-1406.
3. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology. 2010;42:369-373.
4. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20:48-57.
5. Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-Apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013;37:1150-1163.
6. Rao Q, Williamson SR, Zhang S, et al. TFE3 break-Apart FISH has a higher sensitivity for Xp11.2 translocation-Associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013;37:804-815.
7. Clark J, Lu YJ, Sidhar SK, et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene. 1997;15:2233-2239.
8. Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol. 2001;158:2089-2096.
9. Argani P, Antonescu CR, Couturier J, et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol. 2002;26:1553-1566.
10. Argani P, Lui MY, Couturier J, et al. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene. 2003;22:5374-5378.
11. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31:1149-1160.
12. Malouf GG, Su X, Yao H, et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res. 2014;20:4129-4140.
13. Argani P, Aulmann S, Karanjawala Z, et al. Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol. 2009;33:609-619.
14. Chang IW, Huang HY, Sung MT. Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts. Am J Surg Pathol. 2009;33: 1894-1901.
15. Tanaka M, Kato K, Gomi K, et al. Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma. Am J Surg Pathol. 2009;33:1416-1420.
16. Varinot J, Camparo P, Beurtheret S, et al. An adult case of melanotic Xp11 translocation renal cancers: distinct entity or subentity? Int J Surg Pathol. 2011;19:285-289.
17. LeGallo RD, Stelow EB, Sukov WR, et al. Melanotic Xp11.2 neoplasm of the ovary: report of a unique case. Am J Surg Pathol. 2012;36:1410-1414.
18. Ohe C, Kuroda N, Hes O, et al. A renal epithelioid angiomyolipoma/perivascular epithelioid cell tumor with TFE3 gene break visualized by FISH. Med Mol Morphol. 2012;45:234-237.
19. Lee SE, Choi YL, Cho J, et al. Ovarian perivascular epithelioid cell tumor not otherwise specified with transcription factor E3 gene rearrangement: a case report and review of the literature. Hum Pathol. 2012;43:1126-1130.
20. Williamson SR, Bunde PJ, Montironi R, et al. Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol. 2013;37:1619-1626.
21. Liu F, Zhang R, Wang ZY, et al. Malignant perivascular epithelioid cell tumor (PEComa) of cervix with TFE3 gene rearrangement: a case report. Int J Clin Exp Pathol. 2014;7:6409-6414.
22. Ritterhouse LL, Cykowski MD, Hassell LA, et al. Melanotic Xp11 translocation renal cancer: report of a case with a unique intratumoral sarcoid-like reaction. Diagn Pathol. 2014;9:81.
23. Russell CM, Buethe DD, Dickinson S, et al. Perivascular epithelioid cell tumor (PEComa) of the urinary bladder associated with Xp11 translocation. Ann Clin Lab Sci. 2014;44:91-98.
24. Shen Q, Rao Q, Xia QY, et al. Perivascular epithelioid cell tumors (PEComas) with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features. Virchows Arch. 2015; 459:299-306.
25. Schoolmeester JK, Dao LN, Sukov WR, et al. TFE3 translocationassociated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol. 2015;39:394-404.
26. Rao Q, Cheng L, Xia QY, et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology. 2013;62:642-650.
27. Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas with t(6;11)(p21;q12): a clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012;36:1327-1338.
28. Patel RM, Downs-Kelly E, Weiss SW, et al. Dual-color, break-Apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol. 2005;18:1585-1590.
29. Downs-Kelly E, Goldblum JR, Patel RM, et al. The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms. Am J Surg Pathol. 2008;32:8-13.
30. Zhong M, De Angelo P, Osborne L, et al. Dual-color, break-Apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol. 2010;34:757-766.
31. Kim SH, Choi Y, Jeong HY, et al. Usefulness of a break-Apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma. Virchows Arch. 2011;459:299-306.
32. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159: 179-192.
33. Cho HY, Chung DH, Khurana H, et al. The role of TFE3 in PEComa. Histopathology. 2008;53:236-238.
34. Rigby H, Yu W, Schmidt MH, et al. Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate. Pediatr Blood Cancer. 2005;45:202-206.
35. Yu W, Fraser R, Gaskin DA, et al. C-kit-positive metastatic malignant pigmented clear cell epithelioid tumor arising from the kidney in a child without tuberous sclerosis. Ann Diagn Pathol. 2005;9:330-334.
36. Argani P, Lae M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006;24: 1529-1534.
37. Zhong M, Weisman P, Zhu B, et al. Xp11.2 translocation renal cell carcinoma with PSF-TFE3 rearrangement. Diagn Mol Pathol. 2013;22:107-111.
38. Kauffman EC, Ricketts CJ, Rais-Bahrami S, et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014;11:465-475.
39. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34: 1295-1303.
40. Delahunt B, Egevad L, Montironi R, et al. International Society of Urological Pathology (ISUP) consensus conference on renal neoplasia: rationale and organization. Am J Surg Pathol. 2013;37:1463-1468.
41. Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32:103-113.
42. Martignoni G, Pea M, Zampini C, et al. PEComas of the kidney and of the genitourinary tract. Semin Diagn Pathol. 2015;32:140-159.
43. Malinowska I, Kwiatkowski DJ, Weiss S, et al. Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction. Am J Surg Pathol. 2012;36:783-784.
44. Agaram NP, Sung-S, Zhang L, et al. Dichotomy of genetic abnormalities in PEComas with therapeutic implications. Am J Surg Pathol. 2015;39:813-825.
45. Mathur M, Samuels HH. Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Oncogene. 2007;26: 277-283.
46. Kovacs G, Szucs S, De Riese W, et al. Specific chromosome aberration in human renal cell carcinoma. Int J Cancer. 1987;40:171-178.
47. Dijkhuizen T, van den Berg E, Wilbrink M, et al. Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X;autosome translocations. Genes Chromosomes Cancer. 1995;14:43-50.
48. Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003; 27:750-761.
49. Perot C, Boccon-Gibod L, Bouvier R, et al. Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study. Cancer Genet Cytogenet. 2003; 143:93-99.
50. Parast MM, Eudy G, Gow KW, et al. A unique case of renal carcinoma with Xp11.2 translocations/TFE3 gene fusions in a 3-year-old child, with coexistent von Hippel-Lindau gene mutation. Pediatr Dev Pathol. 2004;7:403-406.
51. Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32:656-670.
52. Hintzy MC, Camparo P, Vasiliu V, et al. Renal carcinoma associated with MiTF/TFE translocation: report of six cases in young adults. Prog Urol. 2008;18:275-280.
53. Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009;15:1170-1176.
54. Haudebourg J, Hoch B, Fabas T, et al. A novel case of t(X;1)(p11.2;p34) in a renal cell carcinoma with TFE3 rearrangement and favorable outcome in a 57-year-old patient. Cancer Genet Cytogenet. 2010;200:75-78.
55. Brassesco MS, Valera ET, Bonilha TA, et al. Secondary PSF/TFE3-Associated renal cell carcinoma in a child treated for genitourinary rhabdomyosarcoma. Cancer Genet. 2011;204:108-110.
56. Macher-Goeppinger S, Roth W, Wagener N, et al. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol. 2012;25:308-315.
57. Gaillot-Durand L, Chevallier M, Colombel M, et al. Diagnosis of Xp11 translocation renal cell carcinomas in adult patients under 50 years: interest and pitfalls of automated immunohistochemical detection of TFE3 protein. Pathol Res Pract. 2013;209:83-89.
58. Pflueger D, Sboner A, Storz M, et al. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. Neoplasia. 2013;15:1231-1240.
59. Zhan HQ, Chen H, Wang CF, et al. A case of PSF-TFE3 gene fusion in Xp11.2 renal cell carcinoma with melanotic features. Hum Pathol. 2015;46:476-481.
60. Fox DT, Duronio RJ. Endoreplication and polyploidy: insights into development and disease. Development. 2013;140:3-12.
61. Pan CC, Sung MT, Huang HY, et al. High chromosomal copy number alterations in Xp11 translocation renal cell carcinomas detected by array comparative genomic hybridization are associated with aggressive behavior. Am J Surg Pathol. 2013;37:1116-1119.